Connect Biopharma-2026-JPM.pdf

1、January 2026Corporate Presentation for JPM2This presentation contains“forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995,as amended(the“Act”).Forward-looking statements are statements that are not of historical fact and include,without limitation,st

2、atements regarding future events,our future financial condition,results of operations,business strategy and plans,prospective products(as well as their potential to achieve a differentiated,competitive,or favorable benefit or profile or trend,including on safety,tolerability,improvement,maintenance,

3、clinical response,dosing,efficacy and/or convenience),planned or expected product approval applications or approvals,anticipated milestones,expected data readouts and enrollments,research and development plans and costs,potential future partnerships,expectations about existing partnerships,timing an

4、d likelihood of success,objectives of management for future operations,future results of anticipated product development efforts,and adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements,as well as statements regarding industry trends.The

5、se statements are based on managements current expectations of future events only as of the date of this presentation and are inherently subject to a number of risks,uncertainties and assumptions,some of which cannot be predicted or quantified and some of which are beyond our control,including,among

6、 other things:the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results;whether we will need expanded or additional trials in order to obtain regulatory approval for our product candidates;our ability to obtain and maintain regulatory